Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Zorzou
Markella-Pagona
MP
Stratigos
Alexandros
A
Efstathiou
Eleni
E
Bamias
Aristotle
A
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D012720:Severity of Illness Index
D011799:Quinazolines; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib